Pre-made Petosemtamab benchmark antibody ( Bispecific mAb, anti-EGFR;LGR5 therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;FEX/GPR49/GPR67/GRP49/HG38 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-440
Pre-Made Petosemtamab biosimilar, Bispecific mAb, Anti-EGFR;LGR5 Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;FEX/GPR49/GPR67/GRP49/HG38 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Petosemtamab (also known as MCLA 158) is a bispecific, full length human IgG antibody being developed by Merus, for the treatment of solid tumours including.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Petosemtamab biosimilar, Bispecific mAb, Anti-EGFR;LGR5 Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;FEX/GPR49/GPR67/GRP49/HG38 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|